It remains unclear how hepatic steatosis links to inflammation. Leukocyte cell-derived chemotaxin 2 (LECT2) is a hepatokine that senses fat in the liver and is upregulated prior to weight gain. The aim of this study was to investigate the significance of LECT2 in the development of nonalcoholic steatohepatitis (NASH). In human liver biopsy samples, elevated LECT2 mRNA levels were positively correlated with body mass index (BMI) and increased in patients who have steatosis and inflammation in the liver. LECT2 mRNA levels were also positively correlated with the mRNA levels of the inflammatory genes CCR2 and TLR4. In C57BL/6J mice fed with a high-fat diet, mRNA levels of the inflammatory cytokines Tnfa and Nos2 were significantly lower in Lect2 KO mice. In flow cytometry analyses, the number of M1-like macrophages and M1/M2 ratio were significantly lower in Lect2 KO mice than in WT mice. In KUP5, mouse kupffer cell line, LECT2 selectively enhanced the LPS-induced phosphorylation of JNK, but not that of ERK and p38. Consistently, LECT2 enhanced the LPS-induced phosphorylation of MKK4 and TAB2, upstream activators of JNK. Hepatic expression of LECT2 is upregulated in association with the inflammatory signature in human liver tissues. The elevation of LECT2 shifts liver residual macrophage to the M1-like phenotype, and contributes to the development of liver inflammation. These findings shed light on the hepatokine LECT2 as a potential therapeutic target that can dissociate liver steatosis from inflammation.
Nonalcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease and is closely related to overnutrition, metabolic syndrome, and insulin resistance1. Nonalcoholic steatohepatitis (NASH), which develops in approximately 20% of NAFLD patients, is characterized by hepatocellular injury followed by the development of inflammation and fibrosis. Recent studies suggest that several diverse processes occurring in parallel contribute to the development of liver inflammation2. However, the causal factors that connect overnutrition to liver inflammation are not fully elucidated.
The liver is a major site for the production of bioactive secretory proteins called hepatokines. Several lines of evidence suggest that the dysregulated production of hepatokines, such as selenoprotein P or fetuin-A, are involved in the development of insulin resistance3,4. The leukocyte cell-derived chemotaxin 2 (LECT2) was initially identified as a chemotactic factor for neutrophils5. We rediscovered it as an obesity-associated hepatokine. Hepatic expression of LECT2 is closely associated with body mass index (BMI) in humans and is negatively regulated by the energy depletion-sensing protein adenosine monophosphate-activated protein kinase (AMPK)6. Both LECT2 gene expression in the liver and LECT2 protein levels in the blood are downregulated in mice that have been fasted for 12 h6. In contrast, a high-fat intake for more than 1 week increased LECT2 gene expression in the liver and LECT2 protein levels in the blood of mice6. Specifically, circulating LECT2 levels in the blood reflects the content of hepatic triglycerides rather than body fat, and predicts the onset of weight cycling in mice7. These findings indicate that LECT2 is an energy-sensing hepatokine that is upregulated in response to overnutrition. To date, LECT2 is known to be involved in many pathological conditions, such as sepsis8, diabetes6, systemic amyloidosis9, hepatocarcinogenesis10, NAFLD11, and liver fibrosis12. However, the role of LECT2 in the development of liver inflammation, which can bridge the gap from steatosis to fibrosis in the development of NASH, remains largely unclear.
It has been reported that LECT2 is a modulator of both immune and inflammatory reactions. Lu et al. showed that treatment with LECT2 improves protective immunity by enhancing macrophage functions in septic mice8. Hwang et al. reported that LECT2 induces an atherosclerotic inflammatory reaction via CD209 receptor-mediated c-Jun N-terminal kinase (JNK) phosphorylation in human endothelial cells13. Based on these findings, we hypothesized that LECT2 links overnutrition to the development of liver inflammation and the subsequent development of NASH. In the present study, we tested this hypothesis by investigating the significance of LECT2 gene expression in human liver tissues and the role of LECT2 in liver inflammation and the subsequent development of NASH in a mouse model of inflammation.
Hepatic LECT2 expressions positively correlate with liver inflammation and steatosis
The initial findings of a possible connection between LECT2 and liver inflammation came from our genetic analyses of liver tissue samples from human subjects14,15. The cohort consisted of 32 people with a wide range of BMIs with mild liver steatosis. The clinical backgrounds of the study subjects are shown in Table 1.
We performed liver biopsies and conducted a comprehensive analysis of the gene expression profiles. As we previously reported, LECT2 mRNA levels were positively correlated with BMI (r = 0.609, P = 0.001), but not with serum levels of aspartate transferase (AST), alanine transaminase (ALT), and hemoglobin A1c (HbA1c) (Fig. 1A).
In liver histological findings, LECT2 mRNA expression was higher in patients who have greater than grade1 steatosis than in those who have not (P = 0.02) (Fig. 1C). LECT2 mRNA expression was also higher in patients with greater than grade 1 inflammation and greater than stage 1 fibrosis than those who have not (P = 0.002, 0.02, respectively) (Fig. 1C).
LECT2 mRNA expression levels were also positively correlated with the mRNA expression levels of the inflammatory genes, CCR2 (r = 0.457, P = 0.009) and TLR4 (r = 0.573, P = 0.001) (Fig. 1B). These results indicate that LECT2 mRNA expression is positively associated with obesity and liver inflammation in humans.
Lect2 deficient mice ameliorate HFD-induced liver inflammation
To investigate the potential link between LECT2 and liver inflammation, we fed wild-type and Lect2 KO C57BL6J mice a high-fat diet (HFD) for 4 weeks and then evaluated the inflammatory responses in the liver. Previously, we found that Lect2 mRNA expression in the liver was overwhelmingly dominant compared with that in other tissues in mice5. Therefore we used systemic Lect2 KO mice in the following experiments, although the animal models of liver-specific downregulation for Lect2 might be more suitable. HFD increased body weight in a time-dependent manner (Fig. 2A). We previously observed that Lect 2 KO mice are protected from developing obesity in HFD feeding for as long as 8 weeks6. In the present study, there were no significant differences in the development of hepatic steatosis and body weight between the wild-type and Lect2 KO mice (Fig. 2A,B). Also, the liver weight to body weight ratios and visceral fat weight to body weight ratios were not different between the two genotypes (data not shown). Therefore, we were able to investigate the HFD-induced inflammatory responses without the influences of hepatic steatosis and weight gain. The mRNA levels of two genes involved in the regulation of inflammation, Tnfa and Nos2, were significantly lower in Lect2 KO mice compared with wild-type mice (P = 0.001 and 0.01, respectively) (Fig. 2C). Conversely, the mRNA levels of genes involved in fatty acid synthesis (Fas and Srebp1c) and β-oxidation (Ppara) were not different between the two genotypes (Fig. 2C).
Hepatic M1-like macrophages were decreased in Lect2 deficient mice
The reduction in liver inflammation as a result of Lect2 deficiency prompted us to investigate the subsets of macrophages. To quantify M1- and M2-like macrophages, we performed flow cytometry on the stromal vascular cells (SVCs) that were isolated from liver tissues of wild-type and Lect2 KO mice fed a HFD for 4 weeks. Macrophages were identified as propidium iodide (PI)− CD45+ NK1.1− CD3− CD19− TER119− CD11b+ F4/80+ cells. There were no significant differences in the number of cells expressing Gr-1 and macrophages between wild-type and Lect2 KO mice (Fig. 3A). CD11chigh/CD206low and CD11clow CD206high populations were defined as M1-like and M2-like macrophages, respectively. In flow cytometry analyses, the number of M1-like macrophages and M1/M2 ratio were significantly lower in Lect2 KO mice than in wild-type mice (P = 0.006, P = 0.04, respectively) (Fig. 3A). Additionally, there were no significant differences in the number of M2-like macrophages between wild-type and Lect2 KO mice.
In order to elucidate LECT2 effect in liver residual macrophage, we used KUP5, an immortalized mouse Kupffer cell line established from C57BL/6 strain16. We incubated KUP5 cells with recombinant LECT2 protein and lipopolysaccharide (LPS) for 30 min and checked mitogen-activated protein kinases (MAPKs) including c-jun N-terminal kinase (JNK), extracellular signal-regulated kinases (ERKs), and p38. LPS elevated the phosphorylation of all these MAPK family members, whereas LECT2 alone did not affect the phosphorylation of them. LECT2 selectively enhanced the LPS-induced phosphorylation of JNK, but not that of ERK and p38 (Fig. 3B). Indeed, LECT2 enhanced the LPS-induced phosphorylation of MKK4 and TAB2, upstream activators of JNK (Fig. 3C).
In the present study, we demonstrated that LECT2 is a hepatokine that links obesity to hepatic inflammation via activation of LPS signaling in macrophages (Fig. 4). To the best of our knowledge, this is the first report to demonstrate that LECT2 plays a role in the development of liver inflammation and the progression from simple steatosis to NASH in the liver.
Previously, a two-hit model was proposed for the pathogenesis of NASH; a metabolic syndrome involving liver fat accumulation is the first hit, and the second hit is defined as the progression of fat accumulation to liver inflammation17. Alternatively, a multiple parallel hit model, which is a relatively new concept, has been proposed to explain the development of NASH; namely, many hits act in parallel, and inflammation may precede, rather than follow, steatosis2. Our previous study demonstrated that LECT2 is a hepatokine that senses overnutrition and liver fat accumulation and is upregulated prior to weight gain7. Based on the previous and current findings, we propose that hepatic steatosis and inflammation progress simultaneously during NASH development because liver fat accumulation induces LECT2, which drives inflammation.
To date, it has been reported that LECT2 also contributes to inflammation in many organs. Hwang et al. reported that LECT2 induces atherosclerotic inflammatory reaction in human endothelial cells13. Lu et al. have reported LECT2 treatment improves protective immunity by enhancing macrophage functions in septic mice8. However, the evidence for these inflammatory adaptations in humans remains lacking. In the present study, hepatic expressions of the LECT2 gene was upregulated in tissue samples from patients with hepatic steatosis and inflammation, and both steatosis and inflammation were positively correlated with LECT2 gene expression. LECT2 upregulation may be causal for the subsequent inflammation in humans because Lect2 deficient mice showed downregulated expression of inflammatory genes, such as Tnf and Nos2, in the liver. Even with short term HFD feeding, where body weight and liver steatosis were comparable between wild-type and Lect2 deficient mice, Lect2 deficient mice were protected from the M1-like shift of macrophages and induction of inflammatory genes in the liver.
Tosello et al. reported that macrophages have a crucial role in the early phase of NASH by producing inflammatory cytokines18. Tissue macrophages are phenotypically heterogeneous and are characterized according to their activation status as either 'classically activated' pro-inflammatory macrophages or 'alternatively activated' non-inflammatory macrophages. In the present study, Lect2 deficiency did not change total macrophage number in the liver but reduced M1-like (F4/80+ CD11c+) macrophage number and M1/M2 (F4/80+ CD11c−) ratio of macrophages. Lumeng et al. showed that diet-induced obesity leads to a shift in the activation state of adipose tissue macrophages from an M2-like polarized state to an M1-like pro-inflammatory state, which contributes to insulin resistance19. Itoh et al. reported that a unique histological feature termed the hepatic crown-like structure, which consists of CD11c positive macrophages, is involved in the development of hepatic inflammation and fibrosis, and contributes to the disease progression from simple steatosis to NASH20. Based on these reports, together with our findings, we conclude that the overproduction of LECT2 in the liver may contribute to the M1-like macrophage-dominant phenotype and the subsequent liver inflammation.
JNK is a stress-sensing kinase that is activated by a variety of stimuli, including cytokines, reactive oxygen species, endoplasmic reticulum stress, and metabolic stresses21. Specifically, JNK is phosphorylated and activated by endoplasmic reticulum stress22 and saturated fatty acids23 in cultured hepatocytes as well as by HFD feeding in the liver of mice21,24. JNK activation has a significant role in the development of insulin resistance by inducing the phosphorylation of insulin receptor substrates at specific serine and threonine residues25. We found that Lect2 deficient mice were protected from HFD-induced JNK phosphorylation and insulin resistance in the skeletal muscle6. In adipose tissue-infiltrating macrophages, JNK shifts pro-inflammatory M1-like macrophage polarization and thereby causes insulin resistance26. Based on these findings, we hypothesized that the JNK activation may be responsible for the LECT2-induced shift to M1-like macrophages.
Gut microbiota-derived LPS localizes in the liver of human and experimental NAFLD27 and may induce liver inflammation leading to the development of NASH28. Therefore, we used LPS as one of factors which induces phosphorylation of JNK and enhances inflammation in the liver macrophages. In the present study, LPS activates all of the MAPK family members, such as JNK, ERK, and p38. Treatment with recombinant LECT2 protein specifically enhanced the LPS-induced phosphorylation of JNK, but not that of ERK and p38, in the KUP5 kupffer cells. Consistently, LECT2 enhanced the LPS-induced phosphorylation of MKK4 and TAB2, upstream activators of JNK. These findings suggest that LECT2 specifically enhances the LPS-induced activation of the TAB2-MKK4-JNK axis in the MAPK signaling pathways as an adjuvant.
To date, a specific receptor for LECT2 mediated inflammation has not yet been identified. Unlike the findings in the present study, recombinant LECT2 alone is sufficient to activate JNK and thereby impair insulin signal transduction in C2C12 myotubes6. Also in human endothelial cells, LECT2 directly activates JNK and thereby induces inflammatory cytokines13. Identifying tissue-specific LECT2 receptors and its downstream signaling will help to further clarify the specific pathways leading to inflammation.
In addition, further investigation is needed as to why LECT2 specifically modifies the TAB2-MKK4-JNK signaling among MAPKs. One of candidates that exert the LECT2-mediated specificity in signaling pathway may be a scaffold protein. Previously, it was reported that scaffold protein JIP1 (JNK interaction protein 1) could bind to JNK and not to other MAPK such as p38 and ERK and specifically modify the MAPK signaling pathway29. It might be possible that LECT2 interferes with JIP1 and thereby specify the JNK phosphorylation under the LPS stimulation, the hypothesis that should be tested in future.
In conclusion, the present study demonstrates that hepatic expression of LECT2 is upregulated in association with the inflammatory signature in human liver tissues. The overnutrition-induced elevation of LECT2 activates the LPS-induced TAB2-MKK4-JNK axis as an adjuvant, shifts liver residual macrophages to the M1-like phenotype, and contributes to the development of liver inflammation. These findings shed light on the previously unrecognized function of the hepatokine LECT2 that may be a potential therapeutic target to dissociate liver steatosis from inflammatory signaling.
Patients and methods
Human clinical studies
Liver samples to be analyzed were obtained from 32 patients who underwent liver biopsy for the evaluation of NAFLD. Detailed clinical information about these subjects is presented elsewhere (Table 1).
This study was approved by the regional ethics committee (Medical Ethics Committee of Kanazawa University, No. 194111) All study procedures were in accordance with the Helsinki Declaration, and all study participants provided written informed consent.
Animals and experimental design
C57BL/6J mice (8 week old) were obtained from Sankyo Laboratory Service (Tokyo, Japan). All animals were housed in a 12-h light/12-h dark cycle and allowed free access to food and water. A 60% high-fat diet (HFD; D03062301) was purchased from Research Diets (New Brunswick, NJ).
All animal procedures were in accordance with the standards set forth in the Guidelines for the Care and Use of Laboratory Animals at the Takara-machi campus of Kanazawa University, Japan.
Lect2 knockout mice
Lect2 knockout (KO) mice were produced by homologous recombination using genomic DNA cloned from an Sv-129 P1 library, as described previously30. All experimental mice were generated from an intercross between heterozygous mice.
Blood samples assays in mice
Serum levels of LECT2 were measured by the Ab-Match ASSEMBLY Mouse LECT2 kit (MBL International, Woburn, MA, USA). Fasting serum insulin levels were determined using a mouse insulin ELISA kit (Morinaga Institute of Biological Science, Inc., Yokohama, Japan), according to the manufacturers’ instructions.
Measurement of hepatic triglyceride content in mice
After liver tissue weight was measured, frozen liver tissue was homogenized in 2 mL ice-cold isopropanol. The samples were incubated for 10 min with shaking at room temperature, and the samples were centrifuged at 3000 rpm for 10 min. 1 mL of supernatant was used to measure the hepatic triglyceride content by commercial Triglyceride E-test WAKO kit (Wako Pure Chemical Industries, Osaka, Japan). Results were normalized to the weight of each liver samples.
RNA isolation, cDNA synthesis, and real-time PCR analysis
Total RNA was extracted from mouse liver by RNeasy Tissue Mini Kit (Qiagen). Reverse transcription of total RNA was performed using a high-capacity cDNA archive kit (Applied Biosystems, Foster City, CA). Real-time PCR analysis was performed by TaqMan gene expression assays (Applied Biosystems). Primer sets and TaqMan probes were proprietary to Applied Biosystems (Assays-on-Demand gene expression products).
Preparation of recombinant murine LECT2
Murine LECT2 was prepared as previously described31. Briefly, murine LECT2 was expressed in Expi293 cells (Thermo Fisher Scientific, Waltham, MA, USA) in accordance with the manufacturer’s protocol. The cells were grown for 5–7 days after transfection, and the cell culture supernatant was diluted in 20 mmol/L phosphate buffer without sodium chloride, and potassium chloride, pH 7.2 (buffer A) and loaded onto a HiTrap CM FF column (GE Healthcare Bioscience, Piscataway, NJ, USA) equilibrated with buffer A. After the column was washed with buffer A, the protein was eluted with a linear gradient of 0–1 mol/L sodium chloride. The purified LECT2 was concentrated using VivaSpin (GE Healthcare). To determine the protein concentration, absorbance at 280 nm was measured.
Treatment with recombinant LECT2 protein in KUP5
Studies were peformed using KUP5, mouse kupffer cell line16 (RCB4627, RIKEN BRC). Cells were cultured in 12-well multi plates, in high-glucose DMEM media with 10% fetal bovine serum (FBS), 10 μg/ml bovine insulin, and 250 × 10–6 m 1-thioglycerol. Cells were treated with recombinant LECT2 protein for 30 min with or without LPS.
Western blot studies in KUP5
Western blot studies were performed as previously described6. After the LPS and LECT2 stimulation, treated cells were collected and lysed in 1 × RIPA lysis buffer (Upstate Biotechnology) with a Complete Mini EDTA-free cocktail tablet (Roche Diagnostics) and PhosSTOP phosphatase inhibitor cocktail tablets (Roche Diagnostics). Protein samples were subjected to SDS-PAGE and transferred to polyvinylidene fluoride membranes, using an iBlot gel transfer system (Invitrogen). Membranes were blocked and then they were probed with antibodies for 16 h (Phospho-SAPK/JNK (Thr183/Tyr185) Antibody (Cell Signaling, Danvers, MA), SAPK/JNK Antibody (Cell Signaling, Danvers, MA), Phospho-p38 MAPK (Thr180/Tyr182) Antibody (Cell Signaling, Danvers, MA), p38 MAPK Antibody (Cell Signaling, Danvers, MA), Phospho-p44/42 MAPK(Erk1/2) (Thr202/Tyr204) Antibody (Cell Signaling, Danvers, MA), p44/42 MAPK(Erk1/2) Antibody (Cell Signaling, Danvers, MA) Phospho-SEK1/MKK4 (Ser257) Antibody (Cell Signaling, Danvers, MA), SEK1/MKK4 Antibody (Cell Signaling, Danvers, MA) Afterward, membranes were washed and then incubated with anti-rabbit IgG horseradish peroxidase-linked antibody (Cell Signaling) for 1 h. Protein bands were visualized with ECL Prime Western blotting detection reagent (GE Healthcare UK Ltd.).
Liver tissues from male C57BL/6J mice were minced and digested for 30 min at 37 °C with type II collagenase (Sigma-Aldrich) in PBS containing 2% BSA (pH 7.4). The cell suspension was filtered and then spun at 3000 rpm for 5 min to separate the floating liver tissue fraction from the stromal vascular cell (SVC) pellet. The SVCs were resuspended in PBS supplemented with 2% FBS and incubated with Fc-Block (BD Bioscience).
To determine macrophage phenotype fluorescence-activated cell sorting analysis FACSAriaII (BD Bioscience) was performed using following antibodies, NK1.1-PerCP Cy5.5 (eBioscience, San Diego, CA), CD3-PerCP Cy5.5 (eBioscience, San Diego, CA), CD19-PerCP Cy5.5(eBioscience), TER119-PerCP Cy5.5 (eBioscience, San Diego, CA), CD45-APC-Cy7(eBioscience, San Diego, CA), Gr-1Fluor450 Ly-6G(PB) (eBioscience, San Diego, CA), F4/80-PE-Cy7(Bio Legend, San Diego, CA), CD11b-PETR (Invitrogen, Carlsbad, CA, USA), CD11c-PE(eBioscience, San Diego, CA), CD206 Alexa Fluor 647 (Bio Legend, San Diego, CA). Data analysis and compensation were performed using FlowJo (Tree Star).
All data were analyzed using the Japanese Windows Edition of SPSS version 21.0. Numeric values are reported as the mean ± SEM. Differences between the two groups were assessed using unpaired two-tailed t-tests. Data involving more than two groups were assessed by ANOVA.
Nonalcoholic fatty liver disease
Leukocyte cell-derived chemotaxin 2
Adenosine monophosphate-activated protein kinase
C-Jun N-terminal kinase
Extracellular signal-regulated kinases
Mitogen-activated protein kinases
Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2018).
Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52, 1836–1846 (2010).
Misu, H. et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 12, 483–495 (2010).
Pal, D. et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. 18, 1279–1285 (2013).
Yamagoe, S. et al. Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2. Immunol. Lett. 52, 9–13 (1996).
Lan, F. et al. LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance. Diabetes 63, 1649–1664 (2014).
Chikamoto, K. et al. Rapid response of the steatosis-sensing hepatokine LECT2 during diet-induced weight cycling in mice. Biochem. Biophys. Res. Commun. 478, 1310–1316 (2016).
Lu, X.-J. et al. LECT2 protects mice against bacterial sepsis by activating macrophages via the CD209a receptor. J. Exp. Med. 210, 5–13 (2013).
Mereuta, O. M. et al. Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood 123, 1479–1482 (2014).
Ong, H. T. et al. The tumor suppressor function of LECT2 in human hepatocellular carcinoma makes it a potential therapeutic target. Cancer Gene Ther. 18, 399–406 (2011).
Yoo, H. J. et al. Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis. PLoS ONE 12, 1–11 (2017).
Xu, M. et al. LECT2, a ligand for Tie1, plays a crucial role in liver fibrogenesis. Cell 178, 1478-1492.e20 (2019).
Hwang, H. J. et al. A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression. Biochem. Pharmacol. 98, 157–166 (2015).
Misu, H. et al. Genes involved in oxidative phosphorylation are coordinately upregulated with fasting hyperglycaemia in livers of patients with type 2 diabetes. Diabetologia 50, 268–277 (2007).
Takamura, T. et al. Obesity upregulates genes involved in oxidative phosphorylation in livers of diabetic patients. Obesity 16, 2601–2609 (2008).
Kitani, H., Sakuma, C., Takenouchi, T., Sato, M. & Yoshioka, M. Results in Immunology Establishment of c-myc-immortalized Kupffer cell line from a C57BL/6 mouse strain. Results Immunol. 4, 68–74 (2014).
Paschos, P. & Paletas, K. Non alcoholic fatty liver disease two-hit process: Multifactorial character of the second hit. Hippokratia 13, 128 (2009).
Tosello-Trampont, A. C., Landes, S. G., Nguyen, V., Novobrantseva, T. I. & Hahn, Y. S. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J. Biol. Chem. 287, 40161–40172 (2012).
Lumeng, C. N. et al. Obesity induces a phenotypic switch in adipose tissue macrophage polarization Find the latest version: Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Investig. 117, 175–184 (2007).
Itoh, M. et al. Hepatic crown-like structure: A unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLoS ONE 8(12), e82163 (2013).
Tarantino, G. & Caputi, A. JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. World J. Gastroenterol. 17, 3785–3794 (2011).
Otoda, T. et al. Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and insulin resistance in the liver. Diabetes 62, 811–824 (2013).
Nakamura, S. et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J. Biol. Chem. 284, 14809–14818 (2009).
Hirosumi, J. et al. A central role for JNK in obesity and insulin resistance. Nature 420, 333–336 (2002).
Ozcan, U. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science (80-). 306, 457–461 (2004).
Han, M. S. et al. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science (80-). 339, 218–222 (2013).
Carpino, G. et al. Increased liver localization of lipopolysaccharides in human and experimental NAFLD. Hepatology https://doi.org/10.1002/hep.31056 (2020).
Imajo, K. et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 16, 44–54 (2012).
Whitmarsh, A. J. A Mammalian scaffold complex that selectively mediates MAP kinase activation. Science (80-). 281, 1671–1674 (1998).
Saito, T. et al. Increase in hepatic NKT cells in leukocyte cell-derived chemotaxin 2-deficient mice contributes to severe Concanavalin A-induced hepatitis. J. Immunol. 173, 579–585 (2004).
Kikuchi, A. et al. Plasma half-life and tissue distribution of leukocyte cell-derived chemotaxin 2 in mice. Sci. Rep. https://doi.org/10.1038/s41598-020-70192-x (2020).
We thank M. Kawamura, N. Nishiyama and A. Katayama for technical assistance and H. Misu for useful discussion. This work was partly supported by the following grants: JSPS KAKENHI Grant Numbers 17H06393 (S.K). The English in this document has been checked by Enago (www.enago.com).
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Takata, N., Ishii, Ka., Takayama, H. et al. LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH. Sci Rep 11, 555 (2021). https://doi.org/10.1038/s41598-020-80689-0